Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 8

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
080) 
    $20,691 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

4

ANIXA
BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in
thousands)

    2025  
    2024 

    For
    the nine months ended July 31, 

    2025  
    2024 
  
    Cash
    flows from operating activities: 

    Reconciliation
    of net loss to net cash used in operating activities: 

    Net
    loss 
    $(8,306) 
    $(9,785)
  
    Stock
    option compensation to employees and directors 
     2,822  
     3,440 
  
    Stock
    options issued to consultants 
     77  
     101 
  
    Common
    stock issued to consultants 
     -  
     255 
  
    Amortization
    of operating lease right-of-use asset 
     27  
     28 
  
    Amortization
    of discount on held-to-maturity securities 
     (93) 
     - 
  
    Change
    in operating assets and liabilities: 

    Receivables 
     173  
     (140)
  
    Prepaid
    expenses and other current assets 
     (155)  
     (273)
  
    Accounts
    payable 
     (249) 
     96 
  
    Accrued
    expenses 
     (195) 
     (92)
  
    Operating
    lease liability 
     (19) 
     (38)
  
    Net
    cash used in operating activities 
     (5,918) 
     (6,408)

    Cash
    flows from investing activities: 

    Disbursements
    to acquire short-term investments 
     (36,700) 
     (47,307)
  
    Proceeds
    from maturities of short-term investments 
     40,912  
     50,716 
  
    Net
    cash provided by investing activities 
     4,212  
     3,409 

    Cash
    flows from financing activities: 

    Proceeds